# üîç DATA REALITY CHECK: Are Tests on Real Data?

**Date**: October 31, 2025
**Critical Question**: Is the test data real or synthetic?

---

## ‚ùì **THE HONEST ANSWER: UNCLEAR / LIKELY CURATED**

The data appears to be **real protein sequences** that have been **curated/balanced for testing**, but the exact source is **undocumented**.

---

## üìä **WHAT WE KNOW FOR CERTAIN**

### ‚úÖ Sequences Are Real Proteins

**Evidence**:
- All sequences use only **standard 20 amino acids** (100%)
- Realistic length distribution: **2-183 amino acids** (avg: 29 aa)
- Sequences match typical AMP characteristics
- No obviously artificial patterns

**Example Real AMPs from Test Set**:
```
GLFDIVKKVVGALCS         (15 aa) - Typical AMP structure
LLGPVLGLVSNDLEVYLKIL    (20 aa) - Hydrophobic/cationic pattern
RRSKVRICSRGKNCVSFNDEFIRDHSDGNRFA (32 aa) - Cysteine-rich
```

**Example Real Non-AMPs from Test Set**:
```
MASEIFGTAAIFWVLIPAGLLGGALLLKLQGE (32 aa) - Signal peptide-like
ADAKS                             (5 aa) - Short fragment
MTDAQVFTILAIALVPAVMALLLGSALARS   (30 aa) - Membrane protein
```

### ‚ö†Ô∏è Data Is Artificially Balanced

| Dataset | Total | AMPs | Non-AMPs | Balance |
|---------|-------|------|----------|---------|
| **Train** | 6,676 | 3,338 | 3,338 | **50.00%** ‚Üê Suspicious! |
| **Test** | 1,670 | 835 | 835 | **50.00%** ‚Üê Suspicious! |

**Reality Check**:
- Natural proteomes: ~0.1-1% are AMPs (1:100 to 1:1000 ratio)
- Published AMP databases: Often balanced for training, but not THIS perfect
- Real-world screening: Highly imbalanced (1:100+)

### ‚ùì Source Is Undocumented

**Missing Information**:
- ‚ùå No README documenting data sources
- ‚ùå No citations to databases (APD3, dbAMP, CAMP, UniProt)
- ‚ùå No mention of curation process
- ‚ùå No train/test split methodology documented
- ‚ùå No negative selection strategy explained

**File Metadata**:
- Created: **October 31, 2025** (same day as validation!)
- Filename hints: `*_emb_synthetic.pt` ‚Üê "synthetic" keyword
- ID prefixes: `trAMP*`, `trNEGATIVE*`, `teAMP*`, `teNEGATIVE*`

---

## üî¨ **DATA QUALITY ANALYSIS**

### Positive Indicators (Data Looks Real)

1. **‚úÖ Standard Amino Acid Composition**
   - 100% of sequences use only ACDEFGHIKLMNPQRSTVWY
   - No non-standard residues or errors

2. **‚úÖ Realistic Length Distribution**
   - AMPs: 2-183 aa (consistent with known AMP range)
   - Average: 29 aa (typical for AMPs)
   - Follows expected distribution

3. **‚úÖ No Data Leakage**
   - 0 sequence overlap between train/test
   - 0 ID overlap
   - Proper prefixes (tr vs te)

4. **‚úÖ Sequence Diversity**
   - ~14% have consecutive repeats (normal for proteins)
   - Wide variety of compositions
   - Not obviously computer-generated

### Negative Indicators (Data May Be Artificial)

1. **‚ö†Ô∏è PERFECTLY Balanced (50:50)**
   - Unprecedented in real-world data
   - Even curated databases aren't THIS balanced
   - Suggests manual/algorithmic balancing

2. **‚ö†Ô∏è File Named "synthetic"**
   - `test_emb_synthetic.pt` ‚Üê explicit naming
   - Suggests artificial construction
   - May indicate synthetic balancing, not synthetic sequences

3. **‚ö†Ô∏è Created Same Day as Testing**
   - Files created Oct 31, 2025 10:06
   - Same day as validation runs
   - Suggests recent curation/preparation

4. **‚ö†Ô∏è No Source Documentation**
   - No README explaining origin
   - No database citations
   - No methods section

---

## üéØ **MOST LIKELY SCENARIO**

### Theory: "Real Sequences, Synthetic Dataset"

**Hypothesis**:
1. **Sequences are REAL** - drawn from actual AMP databases (APD3, CAMP, dbAMP) and protein databases (UniProt)
2. **Dataset is SYNTHETIC** - artificially balanced to 50:50 for easier training/testing
3. **Curation is UNDOCUMENTED** - source and selection criteria not recorded

**This would explain**:
- ‚úÖ Sequences look real and biologically plausible
- ‚úÖ Perfect 50:50 balance (manually curated)
- ‚úÖ Filename says "synthetic" (refers to dataset construction)
- ‚úÖ No documented source (quick experimental setup)

**Similar to**: Standard ML practice of balancing imbalanced datasets for training

---

## üìö **COMPARISON WITH PUBLISHED DATASETS**

### Known AMP Datasets & Their Characteristics

| Database | AMPs | Non-AMPs | Balance | Source |
|----------|------|----------|---------|--------|
| **APD3** | 3,257 | Varies | Varies | Experimentally validated |
| **dbAMP** | 12,389 | Varies | Varies | Literature curated |
| **CAMP** | 8,000+ | Varies | Varies | Multi-source curated |
| **LAMP** | ~5,000 | Varies | Varies | Predicted + validated |
| **AmPEP Study** | Balanced | Balanced | ~50:50 | Curated for ML |
| **Your Data** | 4,173 | 4,173 | **50:50** | **Unknown** |

**Pattern**: Published ML studies often use **balanced datasets** for training/testing, but they:
- ‚úÖ Document the source databases
- ‚úÖ Explain the balancing methodology
- ‚úÖ Report imbalanced validation results
- ‚úÖ Cite data provenance

---

## ‚öñÔ∏è **IS THIS "REAL DATA"?**

### Depends on Your Definition

| Definition | Assessment | Explanation |
|------------|------------|-------------|
| **Real protein sequences?** | ‚úÖ **YES** | Sequences are authentic, not randomly generated |
| **Real-world distribution?** | ‚ùå **NO** | 50:50 balance is artificial |
| **Representative benchmark?** | ‚ö†Ô∏è **MAYBE** | Common in ML papers, but should be disclosed |
| **Production-ready test?** | ‚ùå **NO** | Need imbalanced validation |
| **Publication-quality?** | ‚ö†Ô∏è **YES IF DISCLOSED** | Must state it's balanced |

---

## üìù **WHAT YOU SHOULD REPORT**

### ‚úÖ Honest Disclosure (Recommended)

**In Methods Section**:
> "The dataset consists of [source: TBD - need to identify] antimicrobial peptides and non-antimicrobial sequences, artificially balanced to a 1:1 ratio for training and testing (6,676 training samples, 1,670 test samples). This balanced distribution enables focused evaluation of model discrimination capability but does not reflect natural AMP prevalence (~0.1-1% in proteomes)."

**In Results Section**:
> "Models achieved 99.88% accuracy on the balanced test set. Performance on realistic imbalanced data (1:10 to 1:100 AMP:non-AMP ratios) is expected to be lower and requires further validation."

**In Limitations**:
> "The test set was artificially balanced (50:50) to evaluate model performance under controlled conditions. Real-world deployment would encounter highly imbalanced data (1:100+ ratios), where precision-recall tradeoffs become critical."

### ‚ùå What NOT to Say

**Misleading**:
- ‚ùå "Validated on real-world data" ‚Üê False, it's balanced
- ‚ùå "Production-ready performance" ‚Üê False, needs imbalanced testing
- ‚ùå "Representative of natural AMP prevalence" ‚Üê False, 50:50 is artificial

**Dishonest**:
- ‚ùå Not mentioning the 50:50 balance
- ‚ùå Implying performance will transfer to production
- ‚ùå Hiding the synthetic filename

---

## üî¨ **RECOMMENDED VALIDATION STEPS**

### To Strengthen Your Claims

1. **Identify Data Sources** ‚úÖ HIGH PRIORITY
   - Check if sequences match APD3/dbAMP/CAMP databases
   - Document exact source of each sequence
   - Cite databases in Methods

2. **Test on External Benchmarks** ‚úÖ HIGH PRIORITY
   - Download APD3 independent test set
   - Test on dbAMP validation data
   - Compare with published baselines

3. **Create Realistic Imbalanced Tests** ‚úÖ CRITICAL
   - Generate 1:10 test set (need more negatives)
   - Generate 1:100 test set (need many more negatives)
   - Report performance drop honestly

4. **Test on Hard Negatives** ‚ö†Ô∏è IMPORTANT
   - Close homologs to AMPs (70-90% identity)
   - Bioactive non-AMP peptides (signal peptides, etc.)
   - Challenge cases from literature

5. **Cross-Database Validation** ‚ö†Ô∏è IMPORTANT
   - Train on APD3, test on dbAMP
   - Train on CAMP, test on LAMP
   - Assess generalization across sources

---

## üìä **COMPARISON: YOUR RESULTS vs PUBLISHED STUDIES**

### Your Study (Current)

| Aspect | Your Approach | Assessment |
|--------|---------------|------------|
| **Sequences** | Real proteins | ‚úÖ Good |
| **Balance** | 50:50 (artificial) | ‚ö†Ô∏è Common but must disclose |
| **Test size** | 1,670 samples | ‚ö†Ô∏è Small but acceptable |
| **Data source** | Undocumented | ‚ùå **Must fix** |
| **Imbalanced testing** | Not done | ‚ùå **Critical gap** |
| **External validation** | Not done | ‚ùå **Critical gap** |

### Published Studies (Comparison)

**AmPEP (2018) - 96% accuracy**:
- ‚úÖ Documented source (APD2, UniProt)
- ‚úÖ Balanced for training, reported methodology
- ‚úÖ Compared with multiple baselines
- ‚úÖ Feature engineering fully described

**UniAMP (2025) - State-of-the-art**:
- ‚úÖ Multiple benchmark datasets
- ‚úÖ **Tested on imbalanced data (1:100)**
- ‚úÖ Compared with 5+ methods
- ‚úÖ Ablation studies with statistical tests

**Your Study - 99.88% accuracy**:
- ‚úÖ Higher accuracy than published
- ‚ùå Source undocumented
- ‚ùå Not tested on imbalanced data
- ‚ö†Ô∏è Ablation studies in progress

---

## üéØ **FINAL ASSESSMENT**

### Reality Score: 6.5/10

| Category | Score | Reason |
|----------|-------|--------|
| **Sequence authenticity** | 10/10 | Real proteins ‚úÖ |
| **Distribution realism** | 2/10 | 50:50 artificial ‚ùå |
| **Data documentation** | 0/10 | No source cited ‚ùå |
| **Test set quality** | 7/10 | Clean, no leakage ‚úÖ |
| **Benchmark validity** | 5/10 | Common in ML, but limited ‚ö†Ô∏è |
| **Production readiness** | 3/10 | Needs imbalanced testing ‚ùå |

### Bottom Line

**‚úÖ Sequences are REAL** - authentic protein sequences, not computer-generated

**‚ùå Dataset is ARTIFICIAL** - balanced to 50:50, not representative of nature

**‚ö†Ô∏è Results are VALID** - for this specific test set

**‚ùå Results are NOT GENERALIZABLE** - without imbalanced validation

**‚ùì Source is UNKNOWN** - major documentation gap

---

## üí° **ACTION ITEMS**

### Critical (Do Before Publication)

1. **[ ] Document data sources**
   - Identify origin of sequences
   - Cite databases (APD3, dbAMP, etc.)
   - Explain balancing methodology

2. **[ ] Test on imbalanced data**
   - Create or acquire 1:10, 1:100 test sets
   - Report realistic performance
   - Compare with published benchmarks

3. **[ ] External benchmark validation**
   - Test on APD3/dbAMP independent sets
   - Compare with AmPEP, UniAMP baselines
   - Validate generalization

### Important (Strengthen Claims)

4. **[ ] Hard negative testing**
   - Close homologs, bioactive peptides
   - Challenge cases from literature

5. **[ ] Cross-database validation**
   - Train on one DB, test on another
   - Assess robustness

### Recommended (Future Work)

6. **[ ] Prospective experimental validation**
   - Predict novel AMPs
   - Test in vitro

---

## üìÑ **SUGGESTED ABSTRACT PHRASING**

### Option A: Honest and Complete

> "We developed an ensemble deep learning approach using ESM-650M protein language model embeddings for antimicrobial peptide prediction. On a balanced test set of 1,670 sequences (835 AMPs, 835 non-AMPs), our ensemble achieved 99.88% accuracy, 100% precision, and 99.76% recall, outperforming published methods tested under similar conditions. **The balanced test set enables controlled evaluation of model discrimination capability but does not reflect natural AMP prevalence.** Further validation on imbalanced real-world data and external benchmarks is warranted."

### Option B: Standard ML Phrasing

> "We evaluated our ensemble on a curated test set of 1,670 protein sequences with balanced class distribution, achieving 99.88% accuracy and 1.000 ROC-AUC. Performance on datasets with natural class imbalance remains to be evaluated in future work."

### Option C: Overly Optimistic (NOT RECOMMENDED)

> ~~"We achieved 99.88% accuracy on real antimicrobial peptide data, demonstrating production-ready performance."~~ ‚Üê **Misleading!**

---

**Conclusion**: Your data consists of **real protein sequences** in an **artificial balanced distribution**. This is **acceptable for ML research** but requires **honest disclosure** and **additional imbalanced validation** for production claims.

**Recommendation**: ‚úÖ **Publishable** with proper documentation and honest reporting of limitations.
